JETRO and NCC Sign Agreement to Advance ENSEMBLExJ
Overview
The Japan External Trade Organization (JETRO) and the National Cancer Center (NCC) signed an agreement to advance the ENSEMBLExJ (ExJ) Project, a one-stop consultation service for international clinical trials involving six institutions. The project aims to address Japan’s drug lag and drug loss challenges. The partners will work together to publicize the service to overseas biotech companies and connect them with the project, supporting the introduction of medicines to the Japanese market.
Key points
- JETRO and NCC signed a new agreement to advance the ExJ Project.
- ExJ provides strategic support to overseas biotech companies seeking to introduce medicines to the Japanese market, from clinical development through regulatory approval and commercialization.
- JETRO and six national centers will jointly support the discovery of promising overseas companies and their expansion into the Japanese market.
Overview
JETRO (Chairman and CEO: Norihiko Ishiguro) and the National Cancer Center (President: Hiroyuki Mano; hereafter, NCC) signed an agreement to advance the ENSEMBLExJ (ExJ) Project, a one-stop consultation service for international clinical trials, aiming to address Japan’s drug lag and drug loss challenges. The project is operated by six institutions: NCC, the National Center of Neurology and Psychiatry, the National Center for Geriatrics and Gerontology, the Japan Institute for Health Security, the National Cerebral and Cardiovascular Center, and the National Center for Child Health and Development.
Impact
The partners aim to accelerate solutions by combining JETRO’s expertise in supporting investment in Japan and open innovation partnerships, along with its domestic and international networks, with ExJ. In the long term, they aim to create a cycle in the ecosystem for medical innovation in Japan and worldwide.
Details
ExJ provides strategic, hands-on support through clinical development, regulatory approval, and commercialization to help introduce medicines developed by emerging biopharma companies and biotech startups to the Japanese market.
Under the agreement, the partners will publicize the project to overseas companies, connect companies seeking clinical trials or partnerships in Japan with the project, and approach overseas companies the project aims to attract.
At the time the agreement was signed, JETRO and NCC conducted joint promotion with ExJ at BIO Europe in Cologne, Germany, drawing interest in its use from biotech clusters, mainly in Europe. Going forward, the six national centers, with JETRO and NCC serving as the secretariat, will jointly support company discovery and expansion into the Japanese market by combining ExJ with their expertise in investment in Japan and collaboration, taking advantage of opportunities in Japan and overseas where promising biotech companies and clusters gather.
This MOU is scheduled to be presented in the latter half of Part 1 of the Ministry of Health, Labour and Welfare’s “One-Stop Consultation Service for International Clinical Trials” ENSEMBLExJ: Kickoff Symposium. The listed event time is November 13 (Friday), 13:00–17:10, at Room 3 / 4 / 5 on the 5th floor of Bellesalle Tokyo Nihonbashi.